Silver Creek is a clinical-stage biopharmaceutical company with a mission to deliver life-changing medicines to patients in need. Our groundbreaking therapies are designed to target and heal damaged tissues.
Silver Creek is a clinical-stage biopharmaceutical company with a mission to deliver life-changing medicines to patients in need. Our groundbreaking therapies are designed to target and heal damaged tissues.
Our Smart Growth Factor™ technology enables the rapid development of growth factor fusion proteins with broad applicability. Our lead asset is a first-in-class, targeted fusion protein that precisely delivers the cell survival functions of IGF1 to sites of injury.
Our lead asset, scp776, has shown efficacy in preclinical models of stroke, heart attack, and kidney injury. Scp776 is currently under investigation in a Phase II study in stroke patients.
Our lead asset, scp776, has shown efficacy in preclinical models of stroke, heart attack, and kidney injury. Scp776 is currently under investigation in a Phase II study in stroke patients.
